Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Vaccination is Australia’s most important COVID-19 public health action, even though herd immunity is unlikely

View ORCID ProfileE.S. McBryde, View ORCID ProfileM.T. Meehan, View ORCID ProfileJ.M. Caldwell, View ORCID ProfileR. Ragonnet, View ORCID ProfileP. Jayasundara, View ORCID ProfileA. I. Adekunle, M. A. Kuddus, View ORCID ProfileS. Ogunlade, View ORCID ProfileJ.M. Trauer, View ORCID ProfileR.C. Cope
doi: https://doi.org/10.1101/2021.07.16.21260642
E.S. McBryde
1James Cook University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for E.S. McBryde
  • For correspondence: emma.mcbryde@jcu.edu.au
M.T. Meehan
1James Cook University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M.T. Meehan
J.M. Caldwell
2University of Hawaii;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J.M. Caldwell
R. Ragonnet
5Monash University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R. Ragonnet
P. Jayasundara
4University of Monash;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for P. Jayasundara
A. I. Adekunle
3Department of Defence;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. I. Adekunle
M. A. Kuddus
1James Cook University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Ogunlade
1James Cook University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S. Ogunlade
J.M. Trauer
5Monash University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J.M. Trauer
R.C. Cope
6Australian National University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R.C. Cope
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The Australian National Cabinet four-step plan to transition to post-pandemic re-opening begins with vaccination to achieve herd protection and protection of the health system against a surge in COVID-19 cases. Assuming a pre-vaccination reproduction number for the Delta variant of 5, we show that for the current Mixed program of vaccinating over 60s with AstraZeneca and 16-60s with Pfizer we would not achieve herd immunity. We would need to cover 85% of the population (including many 5-16 year-olds to achieve herd immunity).

At lower reproduction number of 3 and our current Mixed strategy, we can achieve herd immunity without vaccinating 5-15 year olds. This will be achieved at a 60% coverage pursuing a strategy targetting high transmitters or 70% coverage using a strategy targetting the vulnerable first. A reproduction number of 7 precludes achieving herd immunity, however vaccination is able to prevent 75% of deaths compared with no vaccination.

We also examine the impact of vaccination on death in the event that herd immunity is not achieved. Direct effects of vaccination on reducing death are very good for both Pfizer and AstraZeneca vaccines. However we estimate that the Mixed or Pfizer program performs better than the AstraZeneca program.

Furthermore, vaccination levels below the herd immunity threshold can lead to substantial (albeit incomplete) indirect protection for both vaccinated and unvaccinated populations. Given the potential for not reaching herd immunity, we need to consider what level of severe disease and death is acceptable, balanced against the consequences of ongoing aggressive control strategies.

The known: SARS CoV-2 variants are known to be more transmissible than the original Wuhan strain, making herd immunity challenging.

The new: We find that vaccinating the older-vulnerable age groups first leads to fewer deaths and is the optimal strategy vaccine coverage is under 70%. Herd immunity achieved solely through vaccinating adults is unlikely, but can still be expected to prevent substantial numbers of deaths.

The implications: Australia is unlikely to achieve herd immunity unless vaccination is combined with substantial public health measures. Even without herd immunity, vaccination remains a highly effective means to mitigate the impact of COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

ESM acknowledges Fellowshhip funding from NHMRC MM acknowledges Fellowship funding from ARC JT acknowledges Fellowshhip funding from NHMRC and project funding from MRFF PJ acknowledges salary support from MRFF these funding agencies have no role in or influence over the study

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

not applicable as this is a mathematical modelling study using publically available data only

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* co-first authors

Data Availability

no original data are used in this manuscript. Original code is in an open online repository, listed in the manuscript

https://covid-19-aithm.shinyapps.io/vaccine_coverage_analysis/

https://github.com/michaeltmeehan/covid19/tree/main/immunization_australia

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 19, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Vaccination is Australia’s most important COVID-19 public health action, even though herd immunity is unlikely
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Vaccination is Australia’s most important COVID-19 public health action, even though herd immunity is unlikely
E.S. McBryde, M.T. Meehan, J.M. Caldwell, R. Ragonnet, P. Jayasundara, A. I. Adekunle, M. A. Kuddus, S. Ogunlade, J.M. Trauer, R.C. Cope
medRxiv 2021.07.16.21260642; doi: https://doi.org/10.1101/2021.07.16.21260642
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Vaccination is Australia’s most important COVID-19 public health action, even though herd immunity is unlikely
E.S. McBryde, M.T. Meehan, J.M. Caldwell, R. Ragonnet, P. Jayasundara, A. I. Adekunle, M. A. Kuddus, S. Ogunlade, J.M. Trauer, R.C. Cope
medRxiv 2021.07.16.21260642; doi: https://doi.org/10.1101/2021.07.16.21260642

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (940)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8967)
  • Forensic Medicine (4)
  • Gastroenterology (417)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1320)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10764)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1815)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4107)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (361)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)